Clinical Trial Protocol
Iranian Registry of Clinical Trials

17 Sep 2026

Comparative bioequivalence study of Ciprofloxacine 500 mg Tablet of Dorsa Pharmaceutical Co. and Ciprobay 500 mg tablet of BAYER as reference in 24 healthy male under fasting.

Protocol summary

Study aim

This study will be performed to compare the pharmacokinetics and invivo parameters of Ciprofloxacin 500 mg tablet formulation as a test product with Ciprobay 500 mg formulation as a reference product and to evaluate the bioequivalence of these two formulations.

Design

Non blinded, randomized, crossover in vivo bioequivalence study in 24 healthy male under fasting condition.

Settings and conduct

In each period, volunteers will receive a single dose intervention (1 or 2) in the Farabi Clinic (Eslamshahr, Tehran).17 blood samples were collected during 72 hours post intervention. A 7-day washout interval separated to study periods.

Participants/Inclusion and exclusion criteria

Healthy subjects (male) between 20 – 45 years of age and Body Mass Index (BMI) within 15% of normal range between 18.5 - 30 kg/m2. Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations. Previous history of allergy to a fluoroquinolone or severe allergic reaction to any medication. History of CNS disorders (e.g. convulsive seizures). History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neuromuscular, psychiatric, auto-immune or neurological disorders.

Intervention groups

Intervention group 1: Ciprofloxacin 500 mg tablet , produced by Dorsa pharmaceutical Co. is the test product. In each period, 12 of 24 subjects will be given a single oral dose of this product. Intervention group 2: Ciprobay 500 mg tablet , produced by BAYER is the reference product. In each period, 12 of 24 subjects will be given a single oral dose of this product.

Main outcome variables

Peak Plasma Concentration

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20180620040164N31**
Registration date: **2022-07-05, 1401/04/14**
Registration timing: **prospective**

Last update: **2022-07-05, 1401/04/14**
Update count: **0**

Registration date

2022-07-05, 1401/04/14

Registrant information

Name

Behzad Montaha Sangari

Name of organization / entity

Noor research and educational institute (Tavan)

Country

Iran (Islamic Republic of)

Phone

+98 21 6600 7026

Email address

info@tavaninstitute.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-07-23, 1401/05/01

Expected recruitment end date

2022-08-06, 1401/05/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparative bioequivalence study of Ciprofloxacine 500 mg Tablet of Dorsa Pharmaceutical Co. and Ciprobay 500 mg tablet of BAYER as reference in 24 healthy male under fasting.

Public title

Comparative in vivo evaluation of 2 Ciprofloxacine 500 mg mg Tablet formulations.

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Healthy subjects (male) between 20 – 45 years of age and Body Mass Index (BMI) within 15% of normal range between 18.5 - 30 kg/m2. Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations. ubjects that have normal vital signs. Subjects who agree with patient consent form.

Exclusion criteria:

Previous history of allergy to a fluoroquinolone or severe allergic reaction to any medication. History of CNS disorders (e.g. convulsive seizures). History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neuromuscular, psychiatric, auto-immune or neurological disorders. Smoking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period. Subjects who has used any drug including prescription or Over-The-Counter (OTC) drugs within 14 days prior to the start of the study and might need drug intake during study period. Heavy drinker of caffeine, grapefruit juice or caffeinated drinks or who are on special diet (such as vegetarians) or do exertional physical activity. A history of difficulty with donating blood or donation of more than 500 ml blood within 7 days prior to the start of the study.

Age

From **20 years** old to **45 years** old

Gender

Male

Phase

Bioequivalence

Groups that have been masked

No information

Sample size

Target sample size: **24**

Randomization (investigator's opinion)

Randomized

Randomization description

The randomization schedule will be generated with https://www.sealedenvelope.com/simple-randomiser/v1/lists. A 2*2 block randomization list is created. We have 12 blocks and within each two volunteer's number (allocated after screening) for all 24 volunteers. According to this list, a treatment sequence of Test/Reference or Reference/Test will be given to each volunteer.

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Crossover

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of School of Pharmacy and Nursing & Midwifery- Shahid Beheshti University of Medica

Street address

Niayesh Highway, Valiasr Ave, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1996835113

Approval date

2021-08-10, 1400/05/19

Ethics committee reference number

IR.SBMU.PHARMACY.REC.1400.113

Health conditions studied

1

Description of health condition studied

Bacterial infections

ICD-10 code

A49.8

ICD-10 code description

Other bacterial infections of unspecified site

Primary outcomes

1

Description

Peak Plasma Concentration (Cmax)

Timepoint

17 blood samples will be withdrawn pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 9, 10, 12, 24, 48 and 72 hours after intervention.

Method of measurement

Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA)

Secondary outcomes

1

Description
AUC (Area Under the Concentration-Time Curve)
Timepoint
17 blood samples will be withdrawn pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 9, 10, 12, 24, 48 and 72 hours after intervention.
Method of measurement
Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA)

Intervention groups

1

Description
Intervention group 1: Ciprofloxacine 500 mg Tablet, produced by Dorsa Pharmaceutical Co. is the test product. In each period, 12 of 24 subjects will be given single oral dose of this product. After 7-day wash-out period the intervention 2 will be given to these subjects.
Category
Treatment - Drugs

2

Description
Intervention group 2: Ciprobay 500 mg tablet, produced by BAYER is the reference product. In each period, 12 of 24 subjects will be given single oral dose of this product. After 7-day wash-out period the intervention 1 will be given to these subjects.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Hakim Farabi Clinic
Full name of responsible person
Ebrahim Siahpoosh
Street address
No. 57, Shemshad alley, in front of Sallor town
City
Tehran
Province
Tehran
Postal code
4635314588
Phone
+98 21 9253 5647
Email
partochem@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Dorsa Pharmaceutical Co.
Full name of responsible person
Amir Esmael Saghafinia
Street address
8th floor; -Fanavari Tarasht Tower; Teimori; Shahid Salehi Blvd
City
Tehran
Province
Tehran
Postal code
1459965204
Phone
+98 21 5461 2000
Email
info@dorsadarou.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Dorsa Pharmaceutical Co.
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Noor Research & Development Institute
Full name of responsible person
Ali Aghaei
Position
Master
Latest degree
Master
Other areas of specialty/work
Pharmacy
Street address
Sharif innovation station, North Habibollah Street, Hosseini Square, Teymoury Street, Tarasht
City
Tehran
Province
Tehran
Postal code

1459926609

Phone

+98 21 6600 4027

Email

partochem@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tavan Institute

Full name of responsible person

Seyed Mohsen Foroutan

Position

Principal investigator

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Sharif innovation station, North Habibollah Street, Hosseini Square, Teymoury Street, Tarasht.

City

Tehran

Province

Tehran

Postal code

1459926609

Phone

+98 21 6600 4027

Email

mforoutan@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Tavan Institute

Full name of responsible person

Ali Aghaei

Position

Master

Latest degree

Master

Other areas of specialty/work

Pharmacy

Street address

Sharif innovation station, North Habibollah Street, Hosseini Square, Teymoury Street, Tarasht.

City

Tehran

Province

Tehran

Postal code

1459926609

Phone

+98 21 6600 4027

Email

partochem@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

It's undetermind yet.

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available